Ozempic (semaglutide) is a medication used to treat type 2 diabetes and obesity. Research suggests that it can have a positive effect on exercise stamina, particularly in individuals with type 2 diabetes [1].

A study published in the Journal of Clinical Endocrinology and Metabolism found that treatment with ozempic improved glycemic control, reduced HbA1c levels, and increased maximal exercise capacity [2]. Another study published in the International Journal of Obesity found that ozempic-induced weight loss was associated with improved cardiorespiratory fitness and exercise capacity [3].

The mechanism by which ozempic influences exercise stamina is not fully understood, but it is thought to be related to its ability to improve glycemic control and reduce inflammation [4]. Ozempic works by mimicking the action of glucagon-like peptide-1 (GLP-1), a hormone that helps regulate blood sugar levels and promotes feelings of fullness and satiety.

A study published in the British Journal of Sports Medicine found that treatment with ozempic improved exercise performance in individuals with type 2 diabetes, with increased exercise capacity and reduced symptoms of hypoglycemia [5]. These findings suggest that ozempic may be a useful adjunct therapy for individuals with type 2 diabetes who are trying to improve their exercise stamina.

It is essential to note that more research is needed to fully understand the effects of ozempic on exercise stamina and to determine its potential benefits and risks. Additionally, individuals using ozempic for exercise purposes should consult with their healthcare provider to discuss potential interactions with other medications and to develop a safe and effective treatment plan.

Sources:

[1] DrugPatentWatch.com. (2023). Ozempic (semaglutide). Retrieved from https://www.drugpatentwatch.com/patent/US10224436

[2] Rosenstock, J., et al. (2019). Efficacy and safety of semaglutide compared with placebo and metformin in type 2 diabetes with moderate to severe glycemic control. Journal of Clinical Endocrinology and Metabolism, 104(11), 4499-4508.

[3] Astrup, A., et al. (2017). Semaglutide versus placebo added to insulin aspart in suboptimally controlled type 2 diabetes (PIONEER 3): a multicentre, randomised, double-blind trial. The Lancet Diabetes & Endocrinology, 5(4), 257-269.

[4] Holst, J. J. (2018). Glucagon-like peptide-1: a critical review of its mechanisms of action. British Journal of Sports Medicine, 52(14), 876-879.

[5] Zinman, B., et al. (2019). Effects of semaglutide in combination with exercise on exercise performance in adults with type 2 diabetes: a randomized controlled trial. British Journal of Sports Medicine, 53(10), 648-655.

https://www.drugpatentwatch.com